Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Status:
RECRUITING
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms. This study aims to examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia.